Clinical Trials
3 trialsNCT02771626 2023-03-17
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc
Phase 1/2 Terminated
NCT04265534 2022-09-21
KEAPSAKE
Calithera Biosciences, Inc
Phase 2 Terminated
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed